Immutep Enters Into A New Collaboration With Merck KGaA, Darmstadt, Germany For LAG-3 Therapy, Efti

NEXT STORY
TRACON Pharmaceuticals Announces Results of Independent Data Monitoring Committee Review of Safety Data from ENVASARC Pivotal Trial
PREV STORY
Paratek Pharmaceuticals Announces FDA Approval of NUZYRA® (omadacycline) Oral Only Dosing Regimen for the Treatment of Community-Acquired Bacterial Pneumonia (CABP)
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Soluble Dietary Fibers Market ($4.54Bn by 2028) Growth Forecast at 4.7% CAGR During 2021 to 2028 COVID Impact and Global Analysis by TheInsightPartners.com

author_avatar
NASDAQ Market News

Biopharmaceutical Leader Robert J. Spiegel, MD, FACP Appointed to the Athenex Board of Directors

author_avatar
NASDAQ Market News

First quantitative diagnostic test validated for Treatment-Free Remission for Eligible Patients with Ph+ CML-CP Treated with Tasigna® Cleared by Health Canada

PORTLAND, Ore. and CAMBRIDGE, Mass., Nov. 13, 2018 (GLOBE NEWSWIRE) -- MolecularMD Corporation received ...

author_avatar
NASDAQ Market News